# NCT05244798 (NCT05244798)

> Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05244798
- Phase: PHASE3
- Status: NOT_YET_RECRUITING
- Sponsor: Sichuan Cancer Hospital and Research Institute
- Conditions: Esophageal Squamous Cell Carcinoma
- Interventions: Sintilimab; radiotherapy; Chemotherapy
- Enrollment: 420
- Primary outcome: Pathology complete response rate, pCR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05244798